Insurance status and disparities in disease presentation, treatment, and outcomes for men with germ cell tumors
Sarah C. Markt(Harvard University), Christopher J. Sweeney(The University of Adelaide), Alexi A. Wright(Harvard University), Brandon A. Mahal(University of Miami), Brandon Bernard(Dana-Farber Brigham Cancer Center), Rowan Miller(Queen Mary University of London), Laurence Albigès(Université Paris-Saclay), Lindsay A. Frazier(Dana (United States)), Clair J. Beard(Oslo University Hospital), Carlos Lago‐Hernandez(Dana-Farber Brigham Cancer Center)
Cited by 63
Related Papers
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
|New England Journal of Medicine|2015|2.8k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial
|Journal of Clinical Oncology|2018|1.1k
Health Care Costs in the Last Week of Life
|Archives of Internal Medicine|2009|900